{"issuance_frequency":"","notes_translated":{"fr":"S'assurer que les promoteurs qui soumettent une présentation de drogue nouvelle disposent des renseignements nécessaires pour se conformer à l'alinéa C.08.002(2)(h), au sous-alinéa C.08.002.1(2)(c)(ii) et au paragraphe C.08.003(3) du Règlement sur les aliments et drogues en ce qui concerne les études de biodisponibilité comparatives et les études de pharmacodynamie comparatives utilisées pour établir l'innocuité et l'efficacité d'un médicament.","en":"To ensure that sponsors of new drug submissions have the information necessary to comply with Sections C.08.002(2)(h), C.08.002.1(2)(c)(ii) and C.08.003(3) of the Food and Drug Regulations with respect to comparative bioavailability and comparative pharmacodynamic studies used in support of the safety and efficacy of a drug."},"issn":"","imso_approval":"true","isbn":"","creator":"","org_section":{"fr":"","en":""},"jurisdiction":"federal","private":false,"maintainer_email":"open-ouvert@tbs-sct.gc.ca","num_tags":0,"edition":"","frequency":"as_needed","data_series_issue_identification":{"fr":"","en":""},"contributor":{"fr":"","en":""},"maintainer":null,"ready_to_publish":"true","id":"9ecfe75c-42ee-43b4-99cf-28f8f9e57bd3","metadata_created":"2021-06-01T19:31:47.516384","subject":["health_and_safety"],"pspc_identification_number":"","metadata_modified":"2021-06-01T19:31:47.516390","author":null,"author_email":null,"geographic_region":[],"portal_release_date":"2021-06-01","digital_object_identifier":"","state":"active","version":null,"keywords":{"fr":["document d'orientation","normes de biodisponibilité comparatives","études pharmacodynamiques comparatives","Règlement sur les aliments et drogues","innocuité d'un médicament"],"en":["guidance document","comparative bioavailability standards","comparative pharmacodynamic studies","Food and Drug Regulations","safety of a drug"]},"relationships_as_object":[],"creator_user_id":"2dc5a12f-2a6f-4822-8514-165ea6bb05d9","title_translated":{"fr":"Ligne directrice - Normes en matière d'études de biodisponibilité comparatives : Formes pharmaceutiques de médicaments à effets systémiques","en":"Guidance Document - Comparative Bioavailability Standards: Formulations Used for Systemic Effects"},"type":"info","resources":[{"cache_last_updated":null,"unique_identifier":"","package_id":"9ecfe75c-42ee-43b4-99cf-28f8f9e57bd3","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"590206ef-1474-4681-9b03-68c36eb9f184","related_relationship":"","name_translated":{"fr":"Ligne directrice - Normes en matière d'études de biodisponibilité comparatives : Formes pharmaceutiques de médicaments à effets systémiques","en":"Guidance Document - Comparative Bioavailability Standards: Formulations Used for Systemic Effects"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document - Comparative Bioavailability Standards: Formulations Used for Systemic Effects","language":["en"],"created":"2021-06-01T19:31:47.582140","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/bioavailability-bioequivalence/comparative-bioavailability-standards-formulations-used-systemic-effects.html#a1.1","last_modified":null,"position":0,"revision_id":"0e0ab07a-bdc6-405d-aa48-f3e722d3f1d8","resource_type":"publication"},{"cache_last_updated":null,"unique_identifier":"","package_id":"9ecfe75c-42ee-43b4-99cf-28f8f9e57bd3","datastore_active":false,"character_set":"","related_type":"","state":"active","id":"ea1e5af2-e18f-4ab9-b9e0-75dc7084e479","related_relationship":"","name_translated":{"fr":"Ligne directrice - Normes en matière d'études de biodisponibilité comparatives : Formes pharmaceutiques de médicaments à effets systémiques","en":"Guidance Document - Comparative Bioavailability Standards: Formulations Used for Systemic Effects"},"hash":"","description":"","format":"HTML","date_published":"","mimetype_inner":null,"url_type":null,"mimetype":null,"cache_url":null,"name":"Guidance Document - Comparative Bioavailability Standards: Formulations Used for Systemic Effects","language":["fr"],"created":"2021-06-01T19:31:47.582145","url":"https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/lignes-directrices/biodisponibilite-bioequivalence/normes-matiere-etudes-biodisponibilite-comparatives-formes-pharmaceutiques-medicaments-effets-systemiques.html#a1.1","last_modified":null,"position":1,"revision_id":"0e0ab07a-bdc6-405d-aa48-f3e722d3f1d8","resource_type":"publication"}],"place_of_publication":[],"num_resources":2,"tags":[],"spatial":"","collection":"publication","org_title_at_publication":{"fr":"Santé Canada","en":"Health Canada"},"date_published":"2018-03-01 00:00:00","issuance":"","groups":[],"license_id":"ca-ogl-lgo","data_series_name":{"fr":"","en":""},"relationships_as_subject":[],"license_title":"Open Government Licence - Canada","restrictions":"unrestricted","organization":{"description":"","created":"2016-09-23T17:25:33.001625","title":"Health Canada | Santé Canada","name":"hc-sc","is_organization":true,"state":"active","image_url":"","revision_id":"6a0471e8-36e5-4217-8f72-563c83e6465a","type":"organization","id":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","approval_status":"approved"},"name":"9ecfe75c-42ee-43b4-99cf-28f8f9e57bd3","isopen":false,"additional_notes":{"fr":"","en":""},"departmental_identification_number":"","notes":"To ensure that sponsors of new drug submissions have the information necessary to comply with Sections C.08.002(2)(h), C.08.002.1(2)(c)(ii) and C.08.003(3) of the Food and Drug Regulations with respect to comparative bioavailability and comparative pharmacodynamic studies used in support of the safety and efficacy of a drug.","owner_org":"BD26DB5E-82D2-42C1-99BB-08FCF6068FEE","program_page_url":{"fr":"","en":""},"url":null,"audience":[],"gc_catalogue_number":"","license_url":"http://open.canada.ca/en/open-government-licence-canada","series_publication_dates":{"fr":"","en":""},"title":"Guidance Document - Comparative Bioavailability Standards: Formulations Used for Systemic Effects","revision_id":"0e0ab07a-bdc6-405d-aa48-f3e722d3f1d8"}